On January 10, 2024, the Connecticut for Accessible Psychedelic Medicine (CAPM) held an online and in person forum with lawmakers and experts in Hartford, Connecticut.
The organization, Connecticut for Accessible Psychedelic Medicine (CAPM) hosted an in person and online public forum in regard to psilocybin mushroom decriminalization (1). The event took place between 10am to 12pm EST. From 12pm to 2pm EST, there will be a public comment period offered and takes place in Hartford, the state capitol of Connecticut (1). It can also be viewed on the Connecticut Network where it will be live streamed as well (1).
As mentioned in Psychedelic Week, the invited speakers in the morning session of the event included (1):
In 2023, a bill to decriminalize psilocybin partially in small amounts, passed the Connecticut House by a 86-64 vote (1). Unfortunately, the bill expired before gaining the chance to receive a final vote from the Senate. Representative Steve Stafstrom has plans to reintroduce the bill some time in 2024 (1). If the bill had passed legislation, it would have imposed a $150 fine but end a criminal penalty for having the possession of under a half an ounce of mushrooms. Some concerns have risen to the surface over law enforcement potentially seeking a boost in policing. These concerns have been raised by the New England Veterans for Plant Medicine and Bay Staters for Natural Medicine (1). Hopefully in 2024, the psilocybin decriminalization bill will be passed in the Connecticut Senate and be established into law.
Reference
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.